Harbor Capital Advisors Inc. lifted its holdings in shares of Evolent Health, Inc. (NYSE:EVH – Free Report) by 140.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 422,421 shares of the technology company’s stock after buying an additional 246,400 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.36% of Evolent Health worth $11,946,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Evolent Health by 0.9% in the first quarter. Vanguard Group Inc. now owns 10,915,070 shares of the technology company’s stock valued at $357,905,000 after buying an additional 93,739 shares in the last quarter. RA Capital Management L.P. increased its stake in shares of Evolent Health by 125.0% during the 1st quarter. RA Capital Management L.P. now owns 5,736,132 shares of the technology company’s stock worth $188,088,000 after purchasing an additional 3,187,000 shares in the last quarter. William Blair Investment Management LLC increased its stake in shares of Evolent Health by 35.2% during the 2nd quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after purchasing an additional 1,308,376 shares in the last quarter. Engaged Capital LLC increased its stake in shares of Evolent Health by 26.1% during the 2nd quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock worth $78,611,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Evolent Health by 5.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,368,255 shares of the technology company’s stock worth $45,286,000 after purchasing an additional 121,770 shares in the last quarter.
Wall Street Analyst Weigh In
EVH has been the subject of a number of recent research reports. Citigroup dropped their price objective on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. KeyCorp started coverage on shares of Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 target price on the stock. Stephens restated an “overweight” rating and set a $42.00 target price on shares of Evolent Health in a research report on Tuesday, July 30th. JMP Securities decreased their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Finally, Truist Financial reiterated a “buy” rating and issued a $33.00 price target on shares of Evolent Health in a report on Tuesday, August 27th. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $38.60.
Insider Buying and Selling at Evolent Health
In other Evolent Health news, General Counsel Jonathan Weinberg sold 42,140 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $31.20, for a total transaction of $1,314,768.00. Following the completion of the transaction, the general counsel now directly owns 167,027 shares of the company’s stock, valued at approximately $5,211,242.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, General Counsel Jonathan Weinberg sold 42,140 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $31.20, for a total transaction of $1,314,768.00. Following the completion of the sale, the general counsel now owns 167,027 shares in the company, valued at approximately $5,211,242.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Seth Blackley sold 187,904 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the sale, the chief executive officer now owns 411,924 shares of the company’s stock, valued at $12,357,720. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 307,291 shares of company stock valued at $9,290,385. 1.60% of the stock is owned by corporate insiders.
Evolent Health Trading Up 0.5 %
Shares of NYSE:EVH opened at $23.46 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The firm has a 50-day simple moving average of $27.80 and a 200 day simple moving average of $25.14.
Evolent Health (NYSE:EVH – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.09. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The business had revenue of $647.10 million during the quarter, compared to analyst estimates of $636.46 million. During the same period in the prior year, the company posted $0.06 EPS. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. On average, sell-side analysts predict that Evolent Health, Inc. will post 0.84 EPS for the current year.
Evolent Health Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Further Reading
- Five stocks we like better than Evolent Health
- Election Stocks: How Elections Affect the Stock Market
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- What Are Dividend Champions? How to Invest in the Champions
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Stock Market Upgrades: What Are They?
- Battle of the Retailers: Who Comes Out on Top?
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE:EVH – Free Report).
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.